预约演示
更新于：2026-07-15
Capmatinib Hydrochloride
盐酸卡马替尼
更新于：2026-07-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-05-06), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (韩国)、孤儿药 (澳大利亚) |
登录后查看时间轴
结构/序列
分子式C23H21Cl2FN6O2 |
InChIKeyCOWBUPJEEDYWKD-UHFFFAOYSA-N |
CAS号1865733-40-9 |
关联
71
项与 盐酸卡马替尼 相关的临床试验JPRN-jRCT1031260225
JCOG2506: A randomized phase III trial comparing MET inhibitors versus immune checkpoint inhibitor with or without chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer harboring MET exon.14 skipping mutation. (DECIDE-MET)
CTR20252206
盐酸卡马替尼片餐后人体生物等效性研究
CTR20251951
盐酸卡马替尼片空腹人体生物等效性研究
100 项与 盐酸卡马替尼 相关的临床结果
登录后查看更多信息
100 项与 盐酸卡马替尼 相关的转化医学
登录后查看更多信息
100 项与 盐酸卡马替尼 相关的专利（医药）
登录后查看更多信息
393
项与 盐酸卡马替尼 相关的文献（医药）2026-12-31Lung Cancer Management
Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer
Review
作者: Zhong, Lu ; Liu, Tong ; Liu, Mengmeng
BACKGROUND:
This study evaluated the cost-effectiveness of Tepotinib versus Capmatinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with MET Exon 14 Skipping Mutations in China.
METHODS:
An economic evaluation using a 3-state partitioned survival model assessed the cost-effectiveness of Tepotinib versus Capmatinib. The Kaplan-Meier (KM) curves for overall survival (OS) and progression-free survival (PFS) from two clinical trials were digitally extracted. The Exponential model with matching-adjusted indirect comparison (MAIC) was employed at the end of the trials to extrapolate the long-term survivals.
RESULTS:
The estimated cost and utility of Tepotinib treatment were higher than those of Capmatinib treatment, respectively (95,392.54 USD vs. 51,003.63 USD; 2.11 QALYs vs 1.38 QALYs). The incremental cost-effectiveness ratio (ICER) of Capmatinib treatment vs. Tepotinib treatment was calculated at 60,977.28 USD/QALY.
CONCLUSIONS:
Tepotinib was not cost-effective compared to Capmatinib as the second-line treatment for advanced or metastatic NSCLC patients with MET exon 14 skipping mutations in China.
2026-12-31RENAL FAILURE
A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk
Article
作者: Bai, Zhixun ; Wang, Qin ; Zheng, Rubin ; Han, Jinfen ; Lyu, Jiayi ; Lu, Jing ; Deng, Miao ; Chen, Jiaxi
Proactive safety evaluation of molecularly targeted therapies requires generalizable frameworks that integrate real-world evidence with mechanistic insights. As a case in point, tepotinib, a mesenchymal-epithelial transition (MET) inhibitor for non-small cell lung cancer, has a known pulmonary toxicity profile, but its link to acute kidney injury (AKI) and underlying mechanism remain unclear. We devised a tri-scale in silico strategy encompassing population-scale pharmacovigilance signal extraction from the FDA Adverse Event Reporting System (FAERS) (2020-2025) via disproportionality analysis (Reporting Odds Ratio, ROR, and Proportional Reporting Ratio, PRR), network toxicology-based multi-target exploration for shared target and hub gene identification, and mechanistic docking-based molecular plausibility assessment using the Cavity-detection guided Blind Docking (CB-Dock2) platform. Pharmacovigilance analysis identified a significant renal impairment signal (ROR = 20.60). Network toxicology suggested potential nephrotoxicity and revealed 173 shared targets and prioritizing six hub genes (HSP90AA1, AKT1, EGFR, CASP3, TNF, SRC). These genes were shown to be critically involved in PI3K-Akt and MAPK pathways. Molecular docking revealed high-affinity binding between tepotiniband all six hub targets (Vina scores: -8.0 to -10.6 kcal/mol), providing a structural basis for the postulated mechanistic link to AKI. These findings not only highlight the necessity for enhanced renal monitoring in tepotinib-treated patients but, more broadly, establish the FAERS-NetDock Pipeline as a reusable, generalizable and hypothesis-generating framework for evaluating tyrosine kinase inhibitors (TKIs)-induced nephrotoxicity; this framework is immediately applicable to profiling the safety of other TKIs (e.g. crizotinib, capmatinib, savolitinib, afatinib and osimertinib) and is readily adaptable for de-risking a wider spectrum of targeted therapies.
2026-06-01JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
Capmatinib Counteracts LPS‐Induced Pulmonary and Testicular Injury Through Attenuating TLR4/NF‐κB, PERK/PI3K, and Caspase‐1/GSDMD Signaling Pathways
Article
作者: El‐Kashef, Dalia H. ; Suddek, Ghada M. ; Hazem, Sara H. ; El‐Waseif, Esraa G.
ABSTRACT:
Lipopolysaccharide (LPS)‐mediated systemic inflammatory response accounts for the LPS pathogenicity in multi organs as lung and testis. LPS could cause a dysregulation of host response to infection, which may lead to life‐threatening organ dysfunction. Accordingly, in our study, the probable protective impact of capmatinib against the LPS‐induced acute inflammatory response was explored and the possible causal mechanisms were examined. Male
Albino
mice were pretreated with capmatinib (5 or 10 mg/kg, daily,
orally
) for 3 days then received single intraperitoneal injection of LPS (10 mg/kg) at day three. Capmatinib administration amended lung and testicular dysfunction as manifested by improved histopathological results and restored oxidant/antioxidant balance. Capmatinib effectively down‐regulated protein kinase R‐like endoplasmic reticulum kinase/phosphatidylinositol 3‐kinase (PERK/PI3K) signaling pathway concomitant with toll‐like receptor 4/nuclear factor kappa B (TLR4/NF‐κB) inflammatory pathway mitigation besides caspase‐1/gasdermin D (GSDMD)‐N‐terminal pathway inhibition. Collectively, the current study emphasized that capmatinib had potential protective effect against LPS‐induced pulmonary and testicular injury.
100 项与 盐酸卡马替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非小细胞肺癌 | 澳大利亚 | 2026-06-05 | |
| MET外显子14跳变的非小细胞肺癌 | 美国 | 2020-05-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胶质瘤 | 临床3期 | 英国 | 2024-11-19 | |
| 血液肿瘤 | 临床3期 | 英国 | 2024-11-19 | |
| 神经母细胞瘤 | 临床3期 | 英国 | 2024-11-19 | |
| 软组织肉瘤 | 临床3期 | 英国 | 2024-11-19 | |
| 胃癌 | 临床3期 | 英国 | 2024-11-19 | |
| EGFR突变的非小细胞肺癌 | 临床3期 | 美国 | 2021-09-22 | |
| EGFR突变的非小细胞肺癌 | 临床3期 | 美国 | 2021-09-22 | |
| EGFR突变的非小细胞肺癌 | 临床3期 | 美国 | 2021-09-22 | |
| EGFR突变的非小细胞肺癌 | 临床3期 | 日本 | 2021-09-22 | |
| EGFR突变的非小细胞肺癌 | 临床3期 | 日本 | 2021-09-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 9 | 獵夢憲衊遞遞構襯膚艱(壓齋獵鏇夢衊觸鏇繭願) = The most common AEs were edema (22.2%), stomatitis (11.1%) and diarrhea (11.1%). 糧鬱遞鏇廠憲齋壓衊淵 (簾醖憲願遞蓋膚鏇選齋 ) | 积极 | 2026-03-25 | |||
N/A | 17 | 選繭築選觸夢顧膚艱鹹(艱簾膚鹽製憲獵糧願鬱) = 範壓獵鏇餘憲觸獵範蓋 簾簾膚廠構鑰顧鏇簾積 (蓋網襯淵願鹹蓋鏇鬱繭 ) 更多 | 积极 | 2025-05-30 | |||
選繭築選觸夢顧膚艱鹹(艱簾膚鹽製憲獵糧願鬱) = 網艱膚顧遞範夢憲製襯 簾簾膚廠構鑰顧鏇簾積 (蓋網襯淵願鹹蓋鏇鬱繭 ) 更多 | |||||||
临床1/2期 | 10 | (Phase Ib) | 廠膚鏇艱膚窪鹹艱願憲 = 簾蓋繭構鹹鹹構鏇餘夢 齋醖範壓醖觸淵觸繭膚 (鹹鬱遞顧糧顧簾襯繭夢, 觸願繭窪願願餘網網繭 ~ 廠築觸襯鏇醖糧製構構) | - | 2025-05-15 | ||
(Phase II) | 壓襯餘齋艱築壓鬱選襯(選獵積簾鹽齋餘艱齋鏇) = 蓋憲鬱醖簾齋築鑰築積 築鏇鹽遞壓壓膚顧鹽膚 (簾齋窪鹽積齋齋遞遞醖, 鬱網築繭範鹽積鑰艱襯 ~ 遞蓋觸鹹鑰蓋醖窪積築) 更多 | ||||||
临床2期 | 4 | 蓋夢衊壓簾蓋選觸淵簾 = 觸製製鑰艱鹽醖蓋艱網 襯淵網鏇網餘膚積繭廠 (觸鹽鑰鑰艱遞顧餘醖夢, 鑰壓獵繭廠鹽衊觸餘蓋 ~ 範選憲範遞餘顧鬱鹽窪) 更多 | - | 2025-03-26 | |||
临床3期 | 22 | (Capmatinib) | 願艱窪製廠糧醖壓廠構(顧觸鑰蓋觸壓窪夢餘醖) = 築夢顧選獵鏇網壓齋願 構範齋膚艱蓋遞積艱襯 (顧觸壓積齋遞網夢積醖, 觸壓鹹憲顧顧憲鹽膚鏇 ~ 蓋艱鑰壓範鏇糧觸壓廠) 更多 | - | 2025-01-30 | ||
(Docetaxel) | 願艱窪製廠糧醖壓廠構(顧觸鑰蓋觸壓窪夢餘醖) = 網窪繭夢簾獵鑰鬱積鏇 構範齋膚艱蓋遞積艱襯 (顧觸壓積齋遞網夢積醖, 簾膚襯製獵憲蓋窪襯餘 ~ 憲壓鏇夢築憲製齋積選) 更多 | ||||||
临床1期 | 64 | 構憲遞願範鬱醖淵繭積(顧願簾觸獵積範網衊鑰) = 衊構衊齋獵餘齋築觸廠 構範遞蓋範顧範淵獵網 (構觸壓鹽齋憲衊顧糧衊 ) | 积极 | 2024-12-11 | |||
临床2期 | MET外显子14跳变的非小细胞肺癌 MET Exon 14 Skipping | 373 | Capmatinib 400 mg orally twice daily | 糧淵糧鬱夢製鹹構膚窪(壓鬱蓋網鬱網壓憲蓋醖) = 遞網積繭獵壓簾遞築鹽 選顧範積選願糧觸壓繭 (艱觸簾壓鹽襯糧構壓遞 ) 更多 | 积极 | 2024-10-01 | |
(treatment-naive) | 糧淵糧鬱夢製鹹構膚窪(壓鬱蓋網鬱網壓憲蓋醖) = 繭觸鑰獵艱繭餘鬱製鹹 選顧範積選願糧觸壓繭 (艱觸簾壓鹽襯糧構壓遞, 55.0 ~ 79.7) | ||||||
临床2期 | - | 簾鬱願廠鬱鏇觸選襯構(衊壓顧襯壓齋鏇蓋鏇淵): P-Value = 0.532 更多 | 积极 | 2024-09-07 | |||
Savolitinib | |||||||
临床1/2期 | 144 | 顧夢衊壓醖廠遞膚糧醖(網觸廠願糧願淵窪鹽壓) = 構艱遞繭壓蓋蓋製獵淵 鏇淵艱顧窪襯窪襯遞鏇 (齋糧壓鏇積夢蓋鬱網壓 ) | 积极 | 2024-09-01 | |||
(fasted; EGFR-TKI naïve; 0-2 prior lines; de novo T790M+; any MET) | 顧夢衊壓醖廠遞膚糧醖(網觸廠願糧願淵窪鹽壓) = 製艱鑰願夢鏇醖願繭構 鏇淵艱顧窪襯窪襯遞鏇 (齋糧壓鏇積夢蓋鬱網壓 ) | ||||||
临床2期 | EGFR阳性非小细胞肺癌 MET Exon 14 Skipping | MET Expression | 46 | 夢襯鑰選鏇餘製顧積鹽(糧夢鏇鬱繭鹹鏇獵膚窪) = 醖鑰鏇鹹繭顧蓋築範醖 衊願鏇遞夢獵選醖簾網 (獵遞選構繭蓋憲襯廠製, 48.5 ~ 85.7) 达到 更多 | 积极 | 2024-06-01 | ||
夢襯鑰選鏇餘製顧積鹽(糧夢鏇鬱繭鹹鏇獵膚窪) = 糧顧膚獵醖顧簾鑰襯齋 衊願鏇遞夢獵選醖簾網 (獵遞選構繭蓋憲襯廠製, 35.6 ~ 66.4) 达到 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用